Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 8.91%
As of Monday, August 17, Ocular Therapeutix, Inc.’s OCUL share price has surged by 8.91%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Commentary & Analysis
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 6.35%
As of Wednesday, August 12, Ocular Therapeutix, Inc.’s OCUL share price has surged by 6.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Is Ocular Therapeutix, Inc. (OCUL) Overvalued?
We dive into why Ocular Therapeutix, Inc. (OCUL) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Rosalio Madrigal
What You Need to Know About Ocular Therapeutix, Inc.'s Q3 Earnings
Ocular Therapeutix, Inc.'s fiscal Q3 earnings report was released on Monday, August 03. Let's dive in to see if (OCUL) missed or beat analyst's expectations.Michael Rose
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 7.63%
As of Thursday, July 16, Ocular Therapeutix, Inc.’s OCUL share price has dipped by 7.63%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,435.5 | $618.0 | 56% |
|
| Shares Out (Mil) | 225.0 | 44.8 | 78% |
|
| Institutional Ownership | 98.6% | 85.3% | 80% |
|
| Float (Mil) | 184.8 | 47.4 | 72% |
|
| Beta | 0.94 | 0.70 | 57% |
|
| Avg Daily Volume (000s) | 3,600 | 390 | 89% |
|
| Price Change (52-week) |
(8.7%) | 68.6% | 37% |
|
| Growth | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 6.7% | 86% |
|
| Net Income (5yr) | (11.3%) | (1.6%) | 28% |
|
| EPS (5yr) | 11.1% | 14.9% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.4%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.352) | ($1.430) | ($1.454) | |
| Month Ago EPS | ($0.388) | ($1.553) | ($1.538) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.388) | ($1.550) | ($1.523) | |
| Year/Year Chg | 0.6% | 0.7% | (27.5%) | |
| Financials | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $52 | $291 | 20% |
|
| Net Income (TTM) (Mil) | ($301) | ($11) | 5% |
|
| EPS (TTM) | ($1.409) | ($0.700) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($238) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $208 | $5 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $76 | $6 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,348 | $450 | 44% |
|
| Valuation | OCUL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.68 | 2.78 | 76% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (342.3%) | 67.0% | 1% |
|
| Net Margin | (579.1%) | (2.3%) | 1% |
|
| ROA | (53.7%) | (22.4%) | 11% |
|
| ROE | (73.0%) | (20.2%) | 12% |
|
| Liabilities to Assets | 22.5% | 32.2% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Ocular Therapeutix, Inc. did not pass any screens on 8/20/2026.
